Background: Insect bite hypersensitivity is an immunoglobulin (Ig)E-mediated dermatitis of horses initiated by bites of midges of the genus Culicoides. Culicoides spp. are not indigenous to Iceland and the prevalence of insect bite hypersensitivity is much higher in horses born in Iceland and exported as compared to Icelandic horses born in a Culicoides rich environment. Immunotherapy is therefore needed. Objectives: The aim of the study was to express an allergen from Culicoides in barley grain and investigate whether an immune response could be obtained in healthy Icelandic horses by oral treatment with transgenic barley expressing the allergen. Study design: In vivo experiment. Methods: The allergen was expressed in barley grain with the Orfeus technique. A device was developed to treat horses orally with barley flour. Four Icelandic horses were treated with transgenic barley and 3 with control barley, in total 500 g in 7 feedings. Serum and saliva samples were collected for measuring specific antibodies. Results: The allergen Cul n 2, a hyaluronidase originating from the salivary gland of Culicoides nubeculosus, was expressed in barley. Horses treated with the transgenic barley mounted a Cul n 2 specific IgG1 and IgG4/7 response in serum and saliva. The serum response was significantly different between the transgenic and control barley treated horses for both subclasses and the saliva response for IgG1. The induced serum antibodies bound to the corresponding allergen from Culicoides obsoletus, rCul o 2 and were able to partially block binding of Cul n 2 as well as Cul o 2 specific IgE from insect bite hypersensitivity affected horses. Main limitations: Small number of horses. Conclusion: This study shows that specific antibody response can be induced in horses not exposed to Culicoides, using oral treatment with transgenic barley expressing an allergen. Further studies will determine whether this approach is a useful alternative for prevention and treatment of equine insect bite hypersensitivity.
Introduction
Insect bite hypersensitivity or summer eczema is a dermatitis of horses caused by Th2 type immunoglobulin (Ig)E mediated hypersensitivity reaction to Culicoides spp. (biting midges). The midges are not found in Iceland and therefore the disease does not occur there [1] . All breeds of horses can be affected, but Icelandic horses born in Iceland and exported to a Culicoides infested environment are more strongly affected than most other breeds [2] . The causative allergens of insect bite hypersensitivity originate in the salivary glands of Culicoides spp. Several allergens from 3 Culicoides species have been isolated and the proteins expressed in Escherichia coli and some in insect cells [3] . The hyaluronidase of Culicoides is one of the allergens causing insect bite hypersensitivity. It has been isolated from Culicoides nubeculosus (Cul n 2) [4] and Culicoides obsoletus (Cul o 2) [5] .
The rising demand for therapeutic proteins has greatly enhanced research on plant-based protein expression because of their eukaryotic protein machinery, improved safety and lower cost. Barley grain is an excellent source of proteins and ideal for stable storage [6] . This is important since cultivation costs are low in proportion to total production costs, and purification constitutes the bulk of the expense [7, 8] . Noninjection routes of allergen specific immunotherapy are becoming more and more applicable [9] . The mucosa of the mouth is an immune privileged site constantly bathed in various antigens derived from food and microbes. Consequently it has an effective immunological network that can enforce tolerogenic mechanisms [10] . The sublingual route has been established for human use as a valid noninvasive alternative to the subcutaneous route [11] . We were interested in investigating whether oral treatment of horses with transgenic barley expressing an allergen was able to induce an antibody response and could be potentially used in the future for preventive and therapeutic oral immunotherapy against insect bite hypersensitivity.
Materials and methods

Generation of Cul n 2 specific monoclonal antibody
A Cul n 2 specific monoclonal antibody (mAb) was generated with the hybridoma technique [12, 13] against rCul n 2 expressed in E. coli (E. colirCul n 2) [4] . Ig positive hybrids were tested on E. coli-rCul n 2 in western blot (WB) according to Jonsdottir et al. [14] except for the secondary antibody that was AP-labeled goat anti-mouse a , dilution 1/5000.
Expression of Cul n 2 in barley grains
The sequence encoding Cul n 2 (GenBank: HM145950.1) was codon optimised for expression in barley b and synthesised c . The gene had N-terminal (HQ) 6 -tag and the expression cassette was under the control of 0.45 kb D-hordein promoter. The expression and production were performed as described before [7] . Two barley lines (No. 19 and 70) were used for stable production. The presence of Cul n 2 protein in the lines was confirmed by WB, as described above with the anti-Cul n 2 mAb, 1/20,000. The amount of Cul n 2 in the barley grain was estimated semiquantitatively using SynGene -GeneTools to compare a known amount of Cul n 2 (expressed in E. coli) to the protein bands in the Cul n 2 barley extract. The samples were analysed in WB in different dilutions, using the Cul n 2 specific mAb, HRP-labeled anti-mouse antibody a and detected with ChemiFast Chemiluminesence d and captured with GENE GNOME SynGene bioimaging d .
Barley mixture and device for oral treatment
The barley grain was ground to a fine powder in a coffee grinder before 200 mmol/L NaCl was added in the ratio 1:2 and mixed. A thickener, Hydroxyethylcellulose Natrosol 250 HHR PC e (CAS: 9004-62-0), 2 g per 50 g barley, was added and stirred for 1 h at RT. The mixture was kept at 4°C overnight. For feeding the barley mixture to the horses, a device in a form of a spiral bit was developed (Fig 1) .
Animals
Seven healthy Icelandic horses, aged 6-8 years, all located in Iceland and thus not exposed to Culicoides, were included in the study. During winter the horses were housed and fed hay and in summertime horses were kept out on pasture. The horses were kept in accordance with the Icelandic animal care guidelines for experimental animals.
Oral treatment and sample collection
Seven horses were treated orally with the barley mixture 6 times with 50-100 g barley grain, equivalent to 5-10 mg of rCul n 2, each time over a period of 20 weeks. In total, they received 400 g of barley grain. Four were treated with transgenic barley expressing Cul n 2 and 3 with normal Golden Promise barley [7] . The horses were boosted with 100 g barley 8 months after the last treatment using the same procedure. The bits were filled using a 30 mL syringe 4-5 times and the treatment lasted 4-6 h. Before treatment and 2 weeks after each treatment blood and saliva were collected. Blood was collected as described previously [14] and saliva was collected with a lacerated tampon, placed in the bit and kept in the mouth of the horses for 2 h. The tampon was placed on a pipette tip in a conical tube and spun at 170 9 g and 4°C. The saliva was collected, spun again at 20,800 9 g for 5 min and kept at À80°C until used.
Enzyme-linked immunosorbent assay
Serum enzyme-linked immunosorbent assay: Allergen specific IgG1, IgG4/7, IgG5, IgE and IgA was measured by enzyme-linked immunosorbent assay (ELISA) in the sera on E. coli-rCul n 2 [4] and rCul o 2 produced in Pichia (Pichia-rCul o 2) [15] by VTU technology f and kindly provided by Boehringer Ingelheim Animal Health GmbH. The plates were coated with 2 lg/mL of each r-protein diluted in 0.2 mol/L Carbonate-Bicarbonate buffer b , pH 9.4 for 2 h at 37°C. Plates were then washed and nonspecific binding sites blocked with 5% dried milk powder and 5% Tween 20 in phosphate-buffered saline g , for 1 h at 37°C. The sera taken before and after treatment (after 400 g barley), and before and after the barley boost, were diluted in blocking buffer, 1:50 for detection of IgG subclasses, 1:10 for IgA and 1:5 for IgE detection, applied to the plates and incubated overnight at 4°C. After washing, mAb 1 lg/mL specific for equine IgE (clone 3H10 [16] ) or for IgG1 (CVS45), IgG4/7 (CVS39), IgG5 (clone 416) [17] or IgA (1:250, clone K129.5G5 h ) were added to the plates and incubated for 2 h at RT. After washing, alkaline-phosphatase-conjugated goat-anti mouse IgG a diluted 1:2000 in blocking buffer was added and incubated for 1½ h at RT. Plates were developed with a solution of a 1.5 mg/mL phosphatase substrate i in 10% diethanolamine i , pH 9.8 and absorbance measured at 405 nm. The results are presented as an ELISA increment where for each horse the OD value before treatment was subtracted from the OD values after barley treatment, before and after the barley boost.
Saliva ELISA: For detection of allergen specific IgG1, IgG4/7, IgG5 and IgA in the saliva, the same ELISA was performed as for the sera except that the saliva was diluted 1:10 and only tested before treatment and after the boost. The results are presented as ELISA increment.
Competitive inhibition ELISA for demonstration of blocking capacity of the induced antibodies
The ability of the horse sera to block IgE-binding of insect bite hypersensitivity-affected horses to E. coli-rCul n 2 and Pichia-rCul o 2 was tested in an inhibition ELISA [14] . The ELISA plates were coated with E. coli-rCul n 2 or Pichia-rCul o 2 and blocked as described above. The sera taken before the treatment and after the barley boost were diluted 1:6, 1:12 and 1:24 and added in duplicates to the plates. After 1 h incubation at 37°C, serum from an insect bite hypersensitivity-affected horse with high Cul n 2 and Cul o 2 specific IgE was added and the ELISA carried out for IgE detection as described above. The percentage of inhibition was calculated for both time points and all dilutions using the following formula:
Competitive inhibition ELISA to demonstrate cross-reactivity between Cul n 2 and rCul o 2 E. coli-rCul n 2, Pichia-rCul o 2 and a negative control recombinant protein (E. coli-rCul n 11 [4] ) were serially diluted 3-fold (0.41-100 lg/mL) in phosphate-buffered saline and incubated with a serum pool for 30 min at RT. The serum pool consisted of the after-boost sera (final dilution 1:50) of the 4 horses treated with Cul n 2 transgenic barley. ELISA plates were coated with E. coli-rCul n 2 and blocked as described above. The preincubated sera were added to the coated plates and incubated at 4°C overnight. Then anti-equine IgG1 antibodies were detected as described above (Serum ELISA). The percentage of inhibition was calculated by setting the absorbance obtained for the serum pool preincubated without recombinant proteins in the fluid phase as 0% inhibition.
Data analysis
Statistical analyses were carried out using the software program NCSS 10 j . A Mann Whitney U test was used to compare antibody increments 
Results
Generation of monoclonal antibody against E. coli produced rCul n 2
The mAb generated against E. coli-rCul n 2 bound to the corresponding protein band in immunoblot both in the form of hybridoma supernatant and ascites (Fig 2a) .
Production of rCul n 2 in barley grain
The screening of the Cul n 2 transgenic barley generations was performed with Cul n 2 specific poly-and monoclonal antibodies (data not shown).
The HQ-tag specific antibody did not react with any of the Cul n 2 grain samples and the protein detected with the Cul n 2 specific antibodies was around 40 kDa, whereas the predicted size should be 50 kDa. We thus assume that a truncated form of the protein was expressed, lacking a part of the amino terminal and thereby the HQ-tag. The expression of Cul n 2 in two T3 generation barley lines, as detected by the Cul n 2 antibodies, is shown in Figure 2b . The amount of rCul n 2 in 1 g of barley grain was estimated at around 100 lg (Fig 2c) . The recombinant Cul n 2 was released from the ground grain in 200 mmol/L NaCl in the ratio 1:2, the mixture used for the oral treatment (Fig 2d) . The rCul n 2 expressed in barley gives a double band in SDS-PAGE (Fig 2b-d) . This might be due to post-translational modification in the barley as opposed to E. coli [7] .
Allergen specific response following oral treatment with Cul n 2 transgenic barley
After barley treatment 3 of the 4 Cul n 2 horses showed an IgG1 response on E. coli-rCul n 2 and Pichia-rCul o 2, and all 4 horses were efficiently boosted (Fig 3) . The difference between the transgenic and control barley treated horses was significant after the boost on both allergens and also after treatment on Pichia-rCul o 2. A very high IgG4/7 background (data not shown) on the E. coli-rCul n 2 allergen made it impossible to distinguish a response even after the boost. However, all the transgenic barley treated horses responded significantly higher on Pichia-rCul o 2 as compared to the control horses, both after treatment and the boost. There was no IgG5 response after treatment and none or only a very low one after the barley boost. No IgE response was detected on E. coli-rCul n 2 and 3 of the 4 transgenic barley treated horses were also IgE negative on Pichia-rCul o 2. However, one of the transgenic barley treated horses showed some IgE response after the barley treatment (Fig 3) . The IgG subclass response was also measured in the saliva before treatment and after the barley boost. There was a significant IgG1 response to both E. coli-rCul n 2 and Pichia-rCul o 2 (Fig 4) . Three out of the 4 transgenic barley treated horses had a higher IgG4/7 response than the controls when tested on the E. coli-rCul n 2, but not on the Pichia-rCul o 2 due to background (Fig 4) . No IgG5 response could be detected in the saliva on E. coli-rCul n 2 but one horse responded on Pichia-rCul o 2 after the barley boost (Fig 4) .
Inhibition of Cul n 2 specific IgE binding by sera from horses treated with Cul n 2 transgenic barley
The IgE blocking capacity of the sera was tested before treatment and 2 weeks after the barley boost. The sera after the boost from the transgenic barley treated horses were able to inhibit binding of serum IgE from an allergic horse to Pichia-rCul o 2. The mean inhibition was 42% (range 17-53%), 23% and 7.5% at serum dilution 1:6, 1:12 and 1:24, respectively. Inhibition was seen to a lower degree with E. coli-rCul n 2 with a mean inhibition of 16% (range 14-20%) at serum dilution 1:6, but further dilutions of the sera did not inhibit IgE binding (data not shown). Inhibition capacity of sera before treatment and sera from the control horses was ≤5% (Fig 5) .
Competitive inhibition ELISA to demonstrate crossreactivity between Cul n 2 and Cul o 2 A competitive inhibition ELISA was performed to confirm that the observed increase in Cul o 2 binding equine IgG1 antibodies after treatment with the transgenic barley was due to cross-reactivity between these 2 proteins. A concentration-dependent inhibition of IgG1-binding to E. coli-rCul n 2 was observed following preincubation of the horse sera with E. coli-rCul n 2 and Pichia-rCul o 2 (Fig 6) . However, while inhibition with E. coli-rCul n 2 reached 90% at a concentration of 100 lg/mL, inhibition with the same amount of Pichia-rCul o 2 only resulted in a 50% inhibition, indicating that the allergens are not fully cross-reactive. Pre-incubation with a negative control recombinant protein (E. coli-rCul n 11) inhibited only marginally and not in a concentration-dependent manner.
Discussion
The mouth is an immune privileged site [10] and, in human oral mucosa, there is abundance of dendritic cells with strong TLR2 and TLR4 expression, which induce a predominantly Th1 and Th17 cells as well as regulatory immune response. There is also negligible presence of inflammatory cells, such as mast cells and eosinophils. Consequently, allergic reactions are rare in the mouth despite heavy trafficking of food proteins and microbes [10] . However, healthy individuals have measurable IgG response to food proteins, especially if consumed in large quantities [18, 19] . Sublingual immunotherapy or allergy treatment via the mucosa of the mouth has given promising results against pollen allergy in humans [20] . We were interested in testing a similar approach against insect bite hypersensitivity in horses. For this purpose, we expressed allergens in barley and developed a device to treat horses. To test the device and the concept, healthy Icelandic horses were treated with transgenic barley grains expressing one allergen and the immune parameters measured.
A flour mixture was made where the rCul n 2 allergen was released from the barley (Fig 2d) and the induction of an immune response was evaluated by measuring Cul n 2 specific antibodies. Furthermore, as many different Culicoides species can induce insect bite hypersensitivity, we also wanted to evaluate whether the oral treatment with an allergen derived from one Culicoides species would result in an immune response against the corresponding allergen derived from another species. This was possible as the hyaluronidase from both C. nubeculosus (E. coli-rCul n 2) and from C. obsoletus (Pichia-rCul o 2) were available. The amino acid identity between Cul n 2 and Cul o 2 is 75% [5] .
The immunoglobulin classes of horses are IgM, IgD, IgG, IgE and IgA and 7 IgG subclasses [21] with different functions. IgG1 and IgG4/7 are thought to be essential for protection against viral and bacterial infections while the IgG3 and IgG5 have been associated with Th2 response and extracellular pathogens [22] . After a treatment period of 20 weeks, the transgenic barley treated horses had a significantly higher IgG1 response against Pichia-rCul o 2 than the controls, whereas the IgG1 response on E. coli-rCul n 2 did not reach significance. This was also the case for IgG4/7, probably due to the fact that the pre-treatment sera showed very high IgG4/7 background on the E. coli-rCul n 2, used in the ELISA. A high IgG4/7 background to E. coli expressed proteins has been observed previously in sera from some horses [14] and may be due to IgG4/7 antibodies against trace amounts of contaminating E. coli proteins present in the recombinant protein (purity of 95% [4] ). No IgG4/7 background reactivity was seen on the Pichia-rCul o 2, as this protein was expressed in yeast (data not shown), and a significant difference was observed between the transgenic barley treated horses and control horses after treatment when tested on PichiarCul o 2 (Fig 3) . Interestingly, both Cul n 2 specific IgG1 and IgG4/7 could be effectively boosted with one barley dose 8 months after the last treatment, and in most transgenic barley treated horses IgG1 and IgG4/7 responses were higher after the boost than after the initial treatment. These IgG1 and IgG4/7 responses were particularly clear when tested on Pichia-rCul o 2 (Fig 3) . To prove that this increase in Cul o 2-specific antibodies was due to cross-reactivity, a competitive inhibition ELISA was done exemplarily for IgG1. Indeed, antigen-specific binding of treatment-induced rCul n 2-IgG1 was inhibited by Pichia-rCul o 2, although, as can be expected, to a lower extent than by rCul n 2, which was the immunogen (Fig 6) .
In the saliva, a significant difference in IgG1 response was observed between the transgenic barley treated horses and the controls on both E. coli-rCul n 2 and Pichia-rCul o 2. The IgG4/7 results were less clear; 3 out of 4 transgenic barley treated horses responded on E. coli-rCul n 2 but only one differed from the control horses on Pichia-rCul o 2 (Fig 4) . The IgG5 response both in serum and saliva was very low or absent. An attempt was made to measure allergen specific IgA but we were not able to show difference between the controls and the transgenic barley treated horses (data not shown). However, one of the transgenic barley treated horses showed a low IgE response in the serum on Pichia-rCul o 2 that increased with the boost. This was not seen with E. coli-rCul n 2 (Fig 3) . Simulium vittatum (black flies) are indigenous in Iceland [23] . A cross-reactivity between Culicoides and Simulium salivary antigens has been shown previously [24] . Although sensitisation to Simulium has not been noted in horses in Iceland, it cannot be excluded that the horse was sensitised prior to the treatment. Consequently, the generation of IgE could be expected as it is well-known in human allergy that allergen specific immunotherapy often induces a raise in allergen specific IgE at the beginning of treatment, followed by a very slow IgE decrease [25] .
Changing the balance towards an allergen specific Th1 response and generating regulatory T cells are crucial factors in successful immunotherapy [26] . Another important immune parameter of induced clinical tolerance is IgG antibodies that have the capacity to inhibit IgEbinding to the specific allergen [27] . Sera from the transgenic barley treated horses were able to partly block the binding of IgE to both E. colirCul n 2 and Pichia-rCul o 2, indicating that the immune response we aimed for had been induced.
Conclusion
We have developed a device and a method for the oral treatment of horses with transgenic barley expressing allergens. Healthy Icelandic horses responded to treatment with barley expressing a C. nubeculosus allergen with a specific IgG response in the blood and saliva. The antibodies induced could partly inhibit IgE-binding to the allergen as well as to the corresponding allergen from another Culicoides species. This pilot study indicates that oral treatment with barley expressing allergens could be a promising option for both prophylactic and therapeutic treatment against insect bite hypersensitivity and deserves further study.
